Cargando…
Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.
Classification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified accord...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033900/ https://www.ncbi.nlm.nih.gov/pubmed/7669590 |
_version_ | 1782136938288906240 |
---|---|
author | Youngson, J. H. Jones, J. M. Chang, J. G. Harris, M. Banergee, S. S. |
author_facet | Youngson, J. H. Jones, J. M. Chang, J. G. Harris, M. Banergee, S. S. |
author_sort | Youngson, J. H. |
collection | PubMed |
description | Classification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients. |
format | Text |
id | pubmed-2033900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1995 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20339002009-09-10 Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. Youngson, J. H. Jones, J. M. Chang, J. G. Harris, M. Banergee, S. S. Br J Cancer Research Article Classification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients. Nature Publishing Group 1995-09 /pmc/articles/PMC2033900/ /pubmed/7669590 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Youngson, J. H. Jones, J. M. Chang, J. G. Harris, M. Banergee, S. S. Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. |
title | Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. |
title_full | Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. |
title_fullStr | Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. |
title_full_unstemmed | Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. |
title_short | Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. |
title_sort | treatment and survival of lymphoid malignancy in the north-west of england: a population-based study. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033900/ https://www.ncbi.nlm.nih.gov/pubmed/7669590 |
work_keys_str_mv | AT youngsonjh treatmentandsurvivaloflymphoidmalignancyinthenorthwestofenglandapopulationbasedstudy AT jonesjm treatmentandsurvivaloflymphoidmalignancyinthenorthwestofenglandapopulationbasedstudy AT changjg treatmentandsurvivaloflymphoidmalignancyinthenorthwestofenglandapopulationbasedstudy AT harrism treatmentandsurvivaloflymphoidmalignancyinthenorthwestofenglandapopulationbasedstudy AT banergeess treatmentandsurvivaloflymphoidmalignancyinthenorthwestofenglandapopulationbasedstudy |